hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06384521 id: STUDY00000500 briefTitle: Lifestyle MIND- Feasibility for Randomized Wait-list Control Trial acronym: MIND overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-04 date: 2025-05 date: 2024-04-25 date: 2024-04-25 name: The University of Texas Health Science Center at San Antonio class: OTHER briefSummary: The goal of this clinical trial is to examine if it is feasible to randomly assign people into two groups and participate in Lifestyle MIND (Mental Illness and/N' Diabetes) at two different times. Lifestyle MIND is a diabetes lifestyle intervention recently developed for people with serious mental illness (SMI). It is known to be helpful for people with SMI who complete it, but the investigators do not know the effect in comparison to those who do not participate in it. The main questions it aims to answer are:
Researchers will compare outcomes of participants in the intervention with those in the wait-list control arm, to see if there will be significant differences in blood glucose level, compliance of diabetes self-management, time staying active, number of emergency department (ED) visits and psychiatric hospitalization, and subjective well-being. conditions: Type 2 Diabetes Mellitus conditions: Serious Mental Illness conditions: Schizophrenia conditions: Major Depression conditions: Bipolar Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Lifestyle MIND measure: Hemoglobin A1c (HbA1c) measure: Summary of Diabetes Self-Care Activities (SDSCA) Questionnaire measure: Hours of Active and Sedentary Behavior measure: Number of emergency department (ED) visits and psychiatric hospitalizations measure: Satisfaction with Life Scale (SWLS) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Texas Health Science Center at San Antonio city: San Antonio state: Texas zip: 78229 country: United States name: Chinyu Wu, PhD role: CONTACT phone: 210-567-8890 email: wuc7@uthscsa.edu name: Chinyu Wu, PhD role: PRINCIPAL_INVESTIGATOR name: Bradley Tragord, ScD role: SUB_INVESTIGATOR lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06384508 id: NL83340.058.23 briefTitle: Decrease Trauma-related Shame With Virtual Reality: The Effectiveness of SHINE-VR acronym: SHINE-VR overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2024-10-31 date: 2024-10-31 date: 2024-04-25 date: 2024-04-25 name: Universiteit Leiden class: OTHER name: University of Amsterdam briefSummary: Suffering from PTSD in childhood can have detrimental formative consequences. Researchers have been eager to develop effective interventions and to enhance treatment motivation since the introduction of the diagnosis of PTSD in the DSM. With evolving understanding of the disorder, its definition and criteria have changed over the course of time. The most recent change involves the addition of the criterium D of negative affects or emotions in relation to PTSD, the feeling of shame amongst others. Individuals experiencing interpersonal trauma, such as sexual abuse, are at high-risk developing trauma-related shame, which in turn can impact the course and effectiveness of PTSD treatment. Shame-inducing situations are typically being avoided, and the feelings are not disclosed to peers and other people. Hence, acknowledging and sharing feelings of shame as well as practicing self-compassion have been proposed to reduce the impact of that negative self-conscious emotion. These aspects get partially tackled in evidence-based trauma therapies, however, there appears to be a need for a more specific trauma-related shame intervention in addition to existing treatments. Recent research has focused on developing such interventions for adults and has reported positive effects.
The goal of this study is to test the effectiveness of a short-term VR shame intervention (SHINE-VR) for adolescents suffering from PTSD after having experienced sexual abuse. The primary objectives of this study to assess the effect of SHINE-VR on trauma-related shame, self-compassion, and PTSD symptom reduction, to investigate whether treatment motivation, an increase in self-compassion, and a decrease in trauma-related shame are associated with PTSD symptom reduction, and the evaluation of SHINE-VR by assessing the feasibility of the intervention. conditions: Shame studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single Case Experimental Design (ABC) with two different baseline lengths primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The participants are unaware of different baseline lengths whoMasked: PARTICIPANT count: 10 type: ESTIMATED name: SHINE-VR measure: Trauma-related shame measure: Self-compassion measure: PTSD symptoms measure: Treatment motivation sex: ALL minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD facility: iMindU Practice for Child, Adolescent and Adult Psychiatry city: Leiden state: South Holland zip: 2311 EX country: Netherlands name: Marie-Jose van Hoof, MD PhD role: CONTACT name: Marie-Jose van Hoof, MD PHD role: PRINCIPAL_INVESTIGATOR lat: 52.15833 lon: 4.49306 facility: LEVVEL city: Amsterdam country: Netherlands name: Ramon Lindauer, Prof. Dr. role: CONTACT lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06384495 id: STUDY00021475 briefTitle: How Does Cerebellar tDCS Alter Intracortical Inhibition Over Time? overallStatus: NOT_YET_RECRUITING date: 2024-08-15 date: 2025-03-31 date: 2025-03-31 date: 2024-04-25 date: 2024-04-25 name: University of Minnesota class: OTHER briefSummary: Combining cortical tDCS with behavioral interventions has been shown to have beneficial outcomes in individuals post-stroke. However, cerebellar tDCS is a fairly new approach for individuals with unilateral cortical stroke and there has not been reports of duration of effect of tDCS applied to the cerebellum in this population.
The purpose of this study is to determine the duration of effect of ventro-lateral cerebellar transcranial direct current stimulation (tDCS) in healthy adults through cortical excitability (CE), cognitive, language and motor assessment measures. Primary aim: Compare baseline CE from left motor cortex of first dorsal interosseous (FDI) and orbicularis oris (OO) areas to CE post cerebellar tDCS at 15 minutes, 45 minutes and 75 minutes. Single-pulse and paired-pulse transcranial magnetic stimulation (TMS) will be used to measure and compare stimulus response curve (S/R curve), cortical silent period (CSP) and short-interval intracortical inhibition (SICI) in the hand area and facial area of the left primary motor cortex at each time point.
Secondary aim: Compare baseline performance on cognition, motor learning and language tasks to performance at 15, 45 and 75 minutes after receiving tDCS. Digit Symbol Substitution Test (DSST), Serial Reaction Time Test (SRTT) and Lexical Decision tasks will be presented via a computer interface. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: REAL-A name: REAL-C name: SHAM measure: stimulus/response curve (S/R Curve) measure: Cortical Silent Period (CSP) measure: Short-interval Intracortical Inhibition (SICI). measure: Digit Symbol Substitution Test (DSST) measure: Serial Reaction Time Test (SRTT) measure: Lexical Decision Task sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384482 id: SNC115-DLL3 CART-101 briefTitle: SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma overallStatus: RECRUITING date: 2024-04-30 date: 2025-04-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-25 name: Shanghai Simnova Biotechnology Co.,Ltd. class: INDUSTRY name: Shanghai Chest Hospital briefSummary: This study is a FIH dose escalation clinical study, with single arm, open label and design, in order to observe the preliminary safety and Pharmacokinetic of SNC115 Injection in participants with Recurrent/refractory small cell lung cancer and Lung large cell neuroendocrine carcinoma. conditions: Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 35 type: ESTIMATED name: SNC115 injection measure: Safety of SNC115 Injection measure: Safety of SNC115 Injection measure: -Efficacy of SNC115 Injection measure: -Efficacy of SNC115 Injection measure: -Efficacy of SNC115 Injection measure: -Efficacy of SNC115 Injection measure: -Efficacy of SNC115 Injection measure: -Efficacy of SNC115 Injection measure: -PK characteristic of SNC115 Injection. measure: -PK characteristic of SNC115 Injection. measure: PK characteristic of SNC115 Injection. measure: PK characteristic of SNC115 Injection. measure: PK characteristic of SNC115 Injection. measure: PK characteristic of SNC115 Injection. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Chest Hospital status: RECRUITING city: Shanghai state: Shanghai zip: 200030 country: China name: Hua Zhong, MD/PhD role: CONTACT phone: 021-22200000 email: ctqxkyy@163.com; eddiedong8@hotmail.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06384469 id: 98984697615 briefTitle: The Impact of Rhinoplasty Approach and Used Autologous Cartilage Grafts on the Nasal Skin-soft Tissue Envelope Metabolism overallStatus: NOT_YET_RECRUITING date: 2025-01-02 date: 2026-01-02 date: 2026-09-01 date: 2024-04-25 date: 2024-04-29 name: University Hospital "Sestre Milosrdnice" class: OTHER briefSummary: This is a prospective observation cohort investigation. Patients, that is participants, undergoing primary functional rhinoplasty will be evaluated in terms of measuring capillary blood lactic acid concentration in the nasal skin-soft tissue envelope immediately after the procedure and 7 days after the procedure.
The aim of our study is to test whether or not different rhinoplasty approaches and volume of the used autologous cartilage grafts impact the nasal skin-soft tissue metabolism. conditions: Rhinoplasty conditions: Nasal Skin-soft Tissue Envelope Metabolism conditions: Lactic Acid conditions: Autologous Cartilage Grafting studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Difference of capillary blood lactic acid concentration in the nasal skin-soft tissue envelope depending on the rhinoplasty approach measure: Correlation between the used autologous cartilage graft volume and lactic acid concentration in the nasal skin-soft tissue envelope sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384456 id: 23-5708 briefTitle: Topical TRanexamic Acid vs. Placebo on Acute Postoperative Pain Following DRF Fixation acronym: TRADR overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2026-06 date: 2026-09 date: 2024-04-25 date: 2024-04-26 name: University Health Network, Toronto class: OTHER briefSummary: The goal of this study is to find out whether the use of topical tranexamic acid (TXA) into the surgical wound will result in less post-operative pain, less pain killer use, and better post-operative use of the wrist in people undergoing surgery for a wrist fracture compared to not using topical TXA (placebo). conditions: Distal Radius Fractures studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Topical TRanexamic Acid name: Placebo measure: acute post-op pain measure: opioid use measure: persistent pain measure: unscheduled hand-related procedures measure: Patient reported function sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Toronto Western Hospital city: Toronto state: Ontario country: Canada name: Ryan Paul, MD role: CONTACT email: ryan.paul2@uhn.ca lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06384443 id: 01001099646 briefTitle: Proton Pump Inhibitors in Cirrhotic Patients overallStatus: COMPLETED date: 2020-10-01 date: 2024-03-01 date: 2024-03-01 date: 2024-04-25 date: 2024-04-25 name: National Liver Institute, Egypt class: OTHER briefSummary: Proton pump inhibitors (PPIs) inappropriate use, in patients with cirrhosis, presents a significant clinical challenge. This study evaluates overprescription and misuse of PPIs in cirrhotic patients. The patterns of use of PPIs will be classified into two groups based on adherence to the proven indications: Group A: Inappropriate use of PPI, Group B: Appropriate use of PPI. We will estimate the prevalence of PPI misuse in cirrhotics and correlate it with different factors. conditions: Proton Pump Inhibitor Adverse Reaction conditions: Liver Cirrhosis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 1000 type: ACTUAL measure: Inappropriate use of PPIs measure: Predictors for inappropriate use of PPIs sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Liver institute - Menoufia University city: Shibīn Al Kawm state: Menoufia zip: 32511 country: Egypt lat: 30.55258 lon: 31.00904 hasResults: False
nctId: NCT06384430 id: MuğlaSKU-NKO briefTitle: Subacromial Impingement Syndrome overallStatus: RECRUITING date: 2024-04-01 date: 2024-08-31 date: 2024-09-01 date: 2024-04-25 date: 2024-04-25 name: Muğla Sıtkı Koçman University class: OTHER briefSummary: Subacromial impingement syndrome is a common shoulder pain disorder. In this study, among the patients who applied to the Physical Medicine and Rehabilitation outpatient clinic of Muğla Training and Research Hospital and were diagnosed with subacromial impingement by anamnesis and clinical tests, inclusion criteria (being between 18-70 years of age, positivity for subacromial impingement syndrome in clinical evaluation (Neer's test, Hawkins Kennedy, supraspinatus palpation test)) and exclusion criteria (under 18 years of age, over 70 years of age, rheumatologic disease diagnosis, symptomatic shoulder osteoarthritis, shoulder instability; shoulder pain in active, passive cervical spine movements, previous shoulder surgery, those with adhesive capsulitis findings (\>50% passive range of motion restriction in 2 planes or full-thickness rotator cuff tear detected on ultrasound), those who received physiotherapy or intra-articular injections in the last 3 months, those with type 2 diabetes or hypothyroidism) will be included in the study. Demographic data of the patients will then be recorded. DASH (Disabilities of the Arm, Shoulder and Hand) and Constant Murley scores will be calculated. 4 years of musculoskeletal ultrasound experience will be recorded by a radiologist using ultrasound (Siemens® V8, LA2-14A probe) in modified Crass position (positioning with the palm of the examined side on the posterior iliac wing) by measuring subacromial bursa thickness, supraspinatus tendon thickness, acromiohumeral distance, supraspinatus tendon thickness/acromiohumeral distance ratio. Demographic data of the patients will then be recorded. DASH (Disabilities of the Arm, Shoulder and Hand) and Constant Murley scores will be calculated. conditions: To Show the Relationship Between Ultrasound Parameters and Shoulder Functional Tests studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 70 type: ESTIMATED name: Shoulder functional tests and ultrasound measure: subacromial bursa thickness measure: supraspinatus tendon thickness measure: acromiohumeral distance sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mugla Egitim Arastima status: RECRUITING city: Mugla country: Turkey name: Nihal KARAYER OZGUL, 1 role: CONTACT lat: 37.21807 lon: 28.3665 hasResults: False
nctId: NCT06384417 id: STUDY00024858 briefTitle: Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2 overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-02 date: 2026-12 date: 2024-04-25 date: 2024-04-25 name: Milton S. Hershey Medical Center class: OTHER briefSummary: The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast, gastro-intestinal, lung, melanoma, head and neck, and/or genito-urinary cancers) treated at Penn State Health clinics and their loved ones perform advance care planning (ACP). The main questions it aims to answer are:
This study is a continuation of NCT06028152. conditions: Breast Cancer conditions: Lung Cancer conditions: Genito-Urinary Cancer conditions: Colorectal Cancer conditions: Gastric Cancer conditions: Pancreatic Cancer conditions: Liver Cancer conditions: Head and Neck Cancer conditions: Melanoma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: INVESTIGATOR count: 32 type: ESTIMATED name: Hello for Cancer game name: Table Topics game measure: Feasibility and Acceptability of modified Hello game measure: Healthcare Utilization measure: Advance Care Planning Engagement Measure measure: Advance Care Planning Surrogate Decision Maker Engagement Measure measure: Satisfaction of Intervention Measure measure: Acceptability of Intervention Measure measure: Preliminary efficacy of Hello on ACP behaviors. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Penn State Cancer Institute city: Hershey state: Pennsylvania zip: 17033 country: United States name: Michael Hayes, PhD role: CONTACT phone: 717-531-8521 email: mhayes3@pennstatehealth.psu.edu name: Michael Hayes, PhD role: SUB_INVESTIGATOR name: Monika Joshi role: SUB_INVESTIGATOR lat: 40.28592 lon: -76.65025 hasResults: False
nctId: NCT06384404 id: 2023-14741 briefTitle: Upfront Surgical Resection for Osteosarcoma acronym: UFSR for OS overallStatus: RECRUITING date: 2024-03-25 date: 2027-12-31 date: 2029-12-31 date: 2024-04-25 date: 2024-04-25 name: Montefiore Medical Center class: OTHER briefSummary: The goal of this pilot study is to learn about patients with newly diagnosed osteosarcoma of an extremity, and whether surgically removing the tumor prior to the administration of any chemotherapy will improve functional outcomes. In order to learn about the patient's experience, the study team will administer questionnaires to the patient and surgeon at various timepoints to assess recovery and the function of the extremity. conditions: Osteosarcoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10 type: ESTIMATED name: Questionnaire measure: Change in Health-Related Quality of Life (HRQoL) score from Historical Controls measure: Event Free Survival sex: ALL minimumAge: 5 Years maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Montefiore Medical Center status: RECRUITING city: Bronx state: New York zip: 10467 country: United States name: Rebecca Zylber role: CONTACT phone: 718-741-2356 email: rzylber@montefiore.org name: Alice Lee, M.D. role: PRINCIPAL_INVESTIGATOR name: David Geller, M.D. role: SUB_INVESTIGATOR lat: 40.84985 lon: -73.86641 hasResults: False
nctId: NCT06384391 id: 4-2023-1730 briefTitle: Intestinal Ultrasound, Magnetic Resonance Enterography, and Conventional Assessment Tools Before and After Treatment of Intestinal Behcet's Disease overallStatus: RECRUITING date: 2024-04-30 date: 2025-06-30 date: 2025-12-31 date: 2024-04-25 date: 2024-04-25 name: Yonsei University class: OTHER briefSummary: Background: The "treat-to-target" approach has recently been adopted in the treatment of inflammatory bowel disease (IBD). The basic premise is to define specific measurable targets and then adjust treatment until these targets are achieved and maintained. According to the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)-Ⅱ statement published in 2021, the long-term treatment targets for IBD are clinical remission, endoscopic healing, absence of disability, restoration of quality of life, and normal growth in children. Symptomatic relief and normalization of serum and fecal markers were determined as short-term targets. Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as measures of the remission depth.
While endoscopic examination assesses the mucosal inflammatory status of the bowel wall, transmural inflammatory status needs to be evaluated with ultrasound, computed tomography (CT), or magnetic resonance enterography (MRE). Ultrasound is advantageous as it does not utilize ionizing radiation and is less costly and uncomfortable for patients, allowing more frequent use. Recent studies suggest that intestinal ultrasound is beneficial in treatment response assessment and planning in patients with Crohn's disease and ulcerative colitis. However, there is a paucity of study regarding the effectiveness of intestinal ultrasound in management of intestinal Behcet's disease. Furthermore, despite its accuracy and comprehensive imaging capabilities without radiation risk, MRE has not been widely used in the diagnosis and follow-up of the patients with intestinal Behcet's disease, and no studies have reported changes in MRE findings after treatment. conditions: Intestinal Behcet Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 55 type: ESTIMATED measure: Accuracy of intestinal ultrasound in identifying endoscopic remission at 26 weeks after initiation of medical treatment measure: Accuracy of intestinal ultrasound in identifying clinical remission at 26 weeks after initiation of medical treatment measure: Accuracies of magnetic resonance enterography in identifying endoscopic and clinical remission at 26 weeks after initiation of medical treatment measure: Accuracies of magnetic resonance enterography in identifying endoscopic and clinical responses at 26 weeks after initiation of medical treatment sex: ALL minimumAge: 19 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yonsei University Health system, Severance Hospital status: RECRUITING city: Seoul zip: 03722 country: Korea, Republic of name: Hyun Kyung Yang role: CONTACT phone: 82-2-2228-7400 email: hkyang@yuhs.ac lat: 37.566 lon: 126.9784 hasResults: False